This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Sylvia L. Brice, MD; Steven K. Spencer, MD
Department of Dermatology Dartmouth-Hitchcock Medical Center Hanover, NH 03755

Arch Dermatol. 1985;121(9):1105-1106.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

In response to the short report by Pavlidakey et al¹ in the ARCHIVES, we, too, were intrigued by the proposal of Finzi et al² that the underlying defect in pityriasis rubra pilaris (PRP) might be a deficiency of retinol binding protein, resulting in inadequate transport of vitamin A to the skin. Their success in treating three patients with stanozolol,³ an anabolic steroid used to elevate the levels of retinol binding protein, was also of great interest. Our experience in using stanozolol in the treatment of PRP, however, has been less encouraging.

In an attempt to duplicate the results of Finzi et al, we gathered a series of five patients with classic adult PRP, diagnosed on clinical grounds with supportive histopathology. As in the case reported by Pavlidakey et al, baseline retinol binding protein levels were within the normal range. Nevertheless, we proceeded with a . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?